Ventyx Biosciences (VTYX) Stifel 2024 Healthcare Conference summary

Strategic focus and portfolio evolution

• Expanded from I&I to include CNS indications, leveraging strong small molecule expertise.

• Rebuilt leadership team with new CMO and IR lead, emphasizing execution and capitalization.

• Portfolio features advanced NLRP3 compounds, considered unmatched in the field.

Scientific rationale and clinical development

• NLRP3 is a key inflammasome linked to IL-1 beta production, impacting multiple inflammatory diseases.

• CNS focus driven by evidence of NLRP3's role in neuroinflammation, especially in microglia.

• Developed CNS-penetrant NLRP3 inhibitor (3232) using a targeted scaffold approach for optimal brain exposure.

• Phase 1 data show robust target engagement at 40 mg, with doses selected to ensure IC90 coverage.

Clinical trial design and indications

• Parkinson's chosen as lead CNS indication due to strong mechanistic rationale and microglia involvement.

• Initial Parkinson's study is a 28-day open-label biomarker trial, focusing on pathway engagement and imaging.

• Obesity and cardiometabolic studies designed to assess broad anti-inflammatory effects, using imaging and biomarkers.

• Three-month safety study in over 100 subjects planned, with extensive biomarker and imaging endpoints.